Industry: Pharmaceuticals (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-02-14 | New | $30,527,397 | $30,527,397 | Equity Only | 06b | SEC link |
| 2024-07-10 | New | $5,000,000 | $5,000,000 | Debt Only | 06b | SEC link |
| 2022-09-02 | New | $24,200,000 | $24,200,000 | Equity Only | 06b | SEC link |
| 2020-11-20 | New | $15,000,000 | $15,000,000 | Equity Only | 06b | SEC link |
| 2020-11-18 | New | $0 | $0 | Other | 06b | SEC link |
| Name | Role |
|---|---|
| Ron Barden | Executive |
| Robert Demeria | Executive |
| Eric Edwards | Director, Executive |
| Glenn Gerecke | Executive |
| Rosemary Gibson | Director |
| Bernard Gupton | Director |
| Daniel Hackman | Executive |
| Melinda Hancock | Director |
| Kerry Ingalls | Director |
| David Levin | Executive |
| James Robert Mooney | Executive |
| Anna Maria Nekoranec | Director |
| Thomas O'malley | Director |
| David Ryan | Executive |
| Andrew Stiles | Executive |
| Marshall Summar | Director |
| Martin Van Trieste | Director |
| Guido Villax | Director |
| Elizabeth Whalley | Executive |
| Elizabeth Whalley Buono | Executive |